According to the FDA label and other sources, such as DrugPatentWatch.com [1], there are certain limitations on the use of ipilimumab, also known as Yervoy, a cancer immunotherapy medication.
For eligible patients, Yervoy is available through various programs that offer discounts and patient assistance. The Patient Access Network (PAN) Foundation, for instance, provides financial assistance to help patients cover out-of-pocket costs [2]. Additionally, Bristol-Myers Squibb, the manufacturer of Yervoy, offers a patient assistance program called the BMS Patient Access Services, which helps eligible patients receive the medication at no cost or at a reduced cost [3].
However, the use of these discounts and patient assistance programs is subject to various eligibility criteria, such as income and insurance status. Additionally, some programs may have restrictions on the number of prescriptions that can be filled at a reduced cost.
It's worth noting that some insurance plans may also have limitations on Yervoy coverage, including restrictions on the number of prescriptions or dosages that can be filled, or requirements for prior authorizations. Patients may need to contact their insurance provider to understand their specific coverage and any out-of-pocket costs that may apply.
Sources:
[1] https://www.drugpatentwatch.com/lawsuit/yervoy-ipilimumab-fda-approval-2011-cancer-treatment
[2] https://www.patientaccess.com/
[3] https://www.bms.com/our-company/about-BMS/commitment-to-access-and-affordability.html